Who are L-Asparagine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Claritin, Glutamin, Fluciclovine PET/CT, Asparagic Acid, 18F-DOPA, GEn (XP13512).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/asparagine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

L-Asparagine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

L-Asparagine (asparagine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

unknown Amino acid transporter Metabolic Live · refreshed every 30 min

Target snapshot

L-Asparagine (asparagine). L-Asparagine works by providing the body with a building block for protein synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
L-Asparagine TARGET	asparagine		unknown		Amino acid transporter
Claritin	loratadine	Generic (originally Schering-Plough)	marketed	Second-generation antihistamine	Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1	1993-04-12
Glutamin	Glutamin	Shahid Beheshti University	marketed		Amino acid transporter
Fluciclovine PET/CT	Fluciclovine PET/CT	OHSU Knight Cancer Institute	marketed	PET imaging agent	Amino acid transporters (LAT1, ASCT2)
Asparagic Acid	ASPARTIC ACID		marketed	Amino Acid [EPC]	Excitatory amino acid transporter 1
18F-DOPA	18F-DOPA	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	phase 3	PET imaging agent	Dopamine synthesis pathway / Large neutral amino acid transporter
GEn (XP13512)	GEn (XP13512)	XenoPort, Inc.	phase 3	Gabapentin prodrug / Anticonvulsant	LAT1 (Large Neutral Amino Acid Transporter 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). L-Asparagine — Competitive Intelligence Brief. https://druglandscape.com/ci/asparagine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing